방법 비교
선택한 방법을 나란히 검토하세요. 서로 다른 행은 강조 표시됩니다.
| 의료 경제학에서의 마르코프 연쇄 모형× | 삶의 질 보정 생명년수 (QALY)× | |
|---|---|---|
| 분야 | 보건경제학 | 보건경제학 |
| 계열 | Process / pipeline | Process / pipeline |
| 기원 연도≠ | 1983 | 1985 |
| 창시자≠ | Beck & Pauker (medical decision analysis, Massachusetts General Hospital) | Alan Williams (Health Economics Research Centre, Oxford University) |
| 유형 | Method | Method |
| 원전≠ | Beck, J. R., & Pauker, S. G. (1983). The Markov Process in Medical Prognosis. Medical Decision Making, 3(4), 419-458. DOI ↗ | Kind, P. (1989). The EuroQol instrument: an index of health-related quality of life. In B. Teeling Smith (Ed.), Measuring health: a practical approach. Chichester: Wiley. link ↗ |
| 별칭≠ | Markov model, state transition model, cohort simulation | QALY, health utility measure |
| 관련 | 5 | 5 |
| 요약≠ | A Markov model is a decision-analytic tool that simulates disease progression through defined health states over time, calculating cumulative costs and quality-adjusted life years (QALYs) to enable cost-effectiveness analysis. Developed by Beck and Pauker in 1983, Markov models are now the standard framework for projecting long-term outcomes of health interventions, especially chronic diseases where patients transition between clinical states (treatment response, disease progression, remission, death). Used by health technology assessment bodies and pharmaceutical companies to predict intervention value beyond trial duration. | A QALY measures health benefit as utility weight (0 = death, 1 = perfect health) multiplied by time lived. Developed by Alan Williams in 1985, QALYs enable comparison of disparate health interventions on a common metric. Used globally by health technology assessment bodies—NICE (UK), HAS (France), CADTH (Canada), WHO—to decide which treatments deserve public funding. |
| ScholarGate데이터셋 ↗ |
|
|